Wegovy is administered once weekly at higher doses than Ozempic, with a maximum maintenance dose of 2.4 mg
Meet our doctors Last reviewed: 19 Jun 2026 Sources Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity, Diabetes, Obesity and Metabolism, [accessed 14 January 2026] Transdermal drug delivery: overcoming the skin's barrier function, Europe PMC [accessed 14 January 2026] (D) Routes of delivery: Case studies: (6) Transdermal delivery of peptides and proteins, Advanced Drug Delivery Reviews, [accessed 14 January 2026] Semaglutide for the treatment of overweight and obesity: A review, Diabetes, Obesity and Metabolism, [accessed 14 January 2026] Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK, [accessed 14 January 2026]
In addition, the proportion of participants discontinuing treatment due to AEs was higher in those receiving survodutide than in those receiving placebo or semaglutide (15.9% vs 5.1% vs 4.0%, respectively)
In contrast, limited solubility may have restricted the potential efficacy of setmelanotide by hampering its systemic exposure
